This site is now managed by the Commonwealth Department of Health and Aged Care. 

Australian Clinical Trials

Clinical Trial Details

Direct Isolation Chemotherapy to Supplement Systemic Intravenous Chemotherapy for those with Liver Metastases from Colorectal Cancer

Print record Print record
Trial Information

Broad Health Condition Cancer

Specific Health ConditionLiver
Bowel - Back passage (rectum) or large bowel (colon)
Bowel - Anal

Trial FocusTreatment

Recruitment Details

Recruitment status

Recruitment State

Sydney Southwest Private Hospital - Liverpool
Sydney Adventist Hospital - Wahroonga
Lake Macquarie Private Hospital - Gateshead
GenesisCare – North Shore - St Leonards
Gold Coast Private Hospital - Southport

2170 - Liverpool
2076 - Wahroonga
2290 - Gateshead
2065 - St Leonards
4215 - Southport

Anticipated date of first participant enrolment10/01/2022

Anticipated date of last participant enrolment1/05/2023

Phase of TrialPhase 1 / Phase 2

Has the study received ethics approval?Further information iconApproved

Trial summary

The aim of this study is to assess the efficacy of delivering chemotherapy treatment through the arteries directly to the liver, bypassing the main blood supply throughout the body.

Who is it for?
You may be eligible for this study if you are aged over 18 years, have hepatic metastases from histologically proven adenocarcinoma of the colon/rectum, and have had some systemic chemotherapy.

Study details
Once enrolled, patients will have baseline scans and will have the AVAS device implanted. The patient will be admitted to hospital up to twice a week to be treated with the liver directed therapy until they have received 5-7 treatments of oxaliplatin, after which the device will be explanted. Oxaliplatin is approved in Australia as chemotherapy treatment for liver metastases from colorectal cancer (via IV infusion), but has not previously been approved when delivered to through the arteries to the liver using the AVAS study device. All patients will also receive Capecitabine from enrolment to 4 weeks after the AVAS explantation as a form of systemic disease management. The patient’s tumour will be scanned 4 weeks after explant of the device, and the patient will be followed up for two years. An additional CT scan will take place 8 weeks after the AVAS explantation which will be used to determine progression free survival for each patient cohort.

The treatment proposed in this study is based on the hypothesis that direct arterial infusion of chemotherapy to metastatic tumours of the liver whilst the blood flow to the organ is isolated could potentially yield benefits that cannot be achieved with existing treatment regimens.


Key inclusion criteria

1. Males or females, aged 18 years or older, with hepatic metastases from histologically proven adenocarcinoma of the colon/rectum;
2. Limited extrahepatic metastases in the lung or lymph nodes;
3. Confirmed non-progressive disease in the liver, per RECIST v1.1, halfway into the first-line systemic chemotherapy regimen after a minimum of 4 cycles of FOLFOX/XELOX ± monoclonal antibodies OR liver-dominant pre-treated or refractory patients;
4. Genotype: RAS mutant for first line patients only. All genetic mutations allowable for pre-treated or refractory patients;
5. Prior treatment with monoclonal antibody treatment is 'greater than or equal to' 4 weeks before implantation;
6. Considered medically fit for repeated general anaesthesia;
7. ECOG performance status 0-1;
8. Adequate bone marrow function (within 14 days of enrolment):
• Haemoglobin greater than or equal to 100 g/L;
• ANC greater than or equal to 1.5 × 10^9/L;
• Platelet Count greater than or equal to 100 × 10^9/L;
9. Adequate renal function (within 14 days of enrolment):
• Serum Creatinine less than or equal to 1.5 × Upper Limit of Normal;
10. Adequate liver function (within 14 days of enrolment):
• Bilirubin less than or equal to 2.0 × Upper Limit of Normal;
• AST less than or equal to 5 × Upper Limit of Normal;
11. Normal coagulation (within 14 days of enrolment):
• INR less than or equal to 1.5
12. Able to understand the risks and benefits of the study and provide signed, written informed consent to participate;
13. Willing and able to comply with all study requirements and assessments;

Minimum age18 Years

GenderBoth males and females

Can Healthy volunteers participate? No

Key exclusion criteria

1. CT-angiogram confirms unsuitable vascular anatomy;
2. No measurable liver disease per RECIST v1.1;
3. Evidence of ascites, cirrhosis, portal hypertension, main portal venous tumour involvement or main portal venous thrombosis;
4. Allergies to contrast agents;
5. Previous hypersensitivity or laryngo-pharyngeal dysaesthesia associated with oxaliplatin;
6. Previous allergies associated with 5-FU or oxaliplatin;
7. Grade > 2 peripheral neuropathy (CTCAE 5.0)
8. Significant co-morbidities;
9. Life expectancy less than or equal to 3 months;
Contact details and further information

Sponsor Primary Sponsor Type: Commercial sector/Industry
Primary Sponsor Name: AllVascular Pty Ltd
Primary Sponsor Address: Suite 13 130-134 Pacific Highway St Leonards NSW 2065
Primary Sponsor Country: Australia

Trial website

Trial IDACTRN12617001268336

Contact person for information and recruitmentDr
Nyan Khin
AllVascular Suite 13 130-134 Pacific Highway St Leonards NSW 2065 Australia
+61 2 9438 5228

Email contact Further information